Dr David Hughes has been appointed to the board of directors, effective immediately. He will also continue with his responsibility for overseeing management of all technical projects and alliances with CN Bio partners as well as managing the internal scientific and engineering teams.
Dr Hughes joined the Company in 2010 as Head of Engineering and was promoted to Technical Director in February 2013 followed by a promotion to Chief Technology Officer in July 2014. He has been pivotal in securing contracts with leading pharmaceutical companies and has been lead principal investigator on several UK, EU and US grants including currently the EU FP7 BIO-MIMETICS project. As co-principal investigator on a $26 Mi US DARPA contract, Dr Hughes has contributed to the strategic direction of this program as well as leading the company’s participation and delivery of milestones under the contract. Prior to joining CN Bio, Dr Hughes graduated from the University of Oxford with a Masters in Engineering Science and Doctorate in Chemical Engineering. After that he spent three years in industry at GSK.
Maureen Coleman, Chairman of CN Bio said ” On behalf of the board of CN Bio Innovations I am delighted to announce that Dr David Hughes has been appointed as a director of the company and will join the board immediately. This clearly recognises David’s growing contribution not only in leading the growth in excellence of science in the company but to its ongoing business and commercial development.”filed under: Business